BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
NYSE:BIO.B - New York Stock Exchange, Inc. - US0905721082 - Common Stock - Currency: USD
Overall BIO.B gets a fundamental rating of 4 out of 10. We evaluated BIO.B against 56 industry peers in the Life Sciences Tools & Services industry. While BIO.B has a great health rating, its profitability is only average at the moment. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO.B was profitable.
In the past year BIO.B had a positive cash flow from operations.
In multiple years BIO.B reported negative net income over the last 5 years.
BIO.B had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIO.B has a worse Return On Assets (-19.69%) than 61.40% of its industry peers.
BIO.B has a Return On Equity of -28.07%. This is comparable to the rest of the industry: BIO.B outperforms 43.86% of its industry peers.
BIO.B has a better Return On Invested Capital (2.70%) than 68.42% of its industry peers.
BIO.B had an Average Return On Invested Capital over the past 3 years of 2.69%. This is significantly below the industry average of 10.31%.
The 3 year average ROIC (2.69%) for BIO.B is below the current ROIC(2.70%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.69% | ||
| ROE | -28.07% | ||
| ROIC | 2.7% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO.B's Operating Margin of 11.85% is fine compared to the rest of the industry. BIO.B outperforms 70.18% of its industry peers.
BIO.B's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 53.77%, BIO.B is in the better half of the industry, outperforming 64.91% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO.B has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.85% | ||
| PM (TTM) | N/A | ||
| GM | 53.77% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO.B has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BIO.B has less shares outstanding
Compared to 5 years ago, BIO.B has less shares outstanding
BIO.B has a worse debt/assets ratio than last year.
2.2 Solvency
BIO.B has an Altman-Z score of 3.69. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
BIO.B has a Altman-Z score of 3.69. This is in the better half of the industry: BIO.B outperforms 71.93% of its industry peers.
BIO.B has a debt to FCF ratio of 4.51. This is a neutral value as BIO.B would need 4.51 years to pay back of all of its debts.
BIO.B has a better Debt to FCF ratio (4.51) than 70.18% of its industry peers.
BIO.B has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BIO.B (0.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 4.51 | ||
| Altman-Z | 3.69 |
ROIC/WACC0.25
WACC10.98%
2.3 Liquidity
BIO.B has a Current Ratio of 6.48. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.48, BIO.B is in the better half of the industry, outperforming 78.95% of the companies in the same industry.
BIO.B has a Quick Ratio of 4.85. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BIO.B (4.85) is better than 77.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.48 | ||
| Quick Ratio | 4.85 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased strongly by -12.40% in the last year.
Measured over the past 5 years, BIO.B shows a small growth in Earnings Per Share. The EPS has been growing by 7.84% on average per year.
BIO.B shows a decrease in Revenue. In the last year, the revenue decreased by -3.92%.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-12.4%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-6.45%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-2.01%
3.2 Future
Based on estimates for the next years, BIO.B will show a small growth in Earnings Per Share. The EPS will grow by 7.00% on average per year.
Based on estimates for the next years, BIO.B will show a small growth in Revenue. The Revenue will grow by 3.94% on average per year.
EPS Next Y-4.93%
EPS Next 2Y5.37%
EPS Next 3Y5.75%
EPS Next 5Y7%
Revenue Next Year0.27%
Revenue Next 2Y2.5%
Revenue Next 3Y3.15%
Revenue Next 5Y3.94%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.78, BIO.B can be considered very expensive at the moment.
Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than 73.68% of the companies in the same industry.
BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 29.35, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 27.12, which means the current valuation is very expensive for BIO.B.
Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than 64.91% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.10. BIO.B is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.78 | ||
| Fwd PE | 27.12 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued a bit cheaper than 73.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.96 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.29
EPS Next 2Y5.37%
EPS Next 3Y5.75%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (3/3/2025, 8:14:54 PM)
265.82
-53.55 (-16.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners84.5%
Inst Owner Change-0.56%
Ins Owners3.65%
Ins Owner ChangeN/A
Market Cap7.44B
Analysts78.18
Price Target357.4 (34.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.08%
Min EPS beat(2)0.1%
Max EPS beat(2)72.05%
EPS beat(4)4
Avg EPS beat(4)32.67%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)6
Avg EPS beat(8)15.85%
EPS beat(12)8
Avg EPS beat(12)14.81%
EPS beat(16)12
Avg EPS beat(16)21.47%
Revenue beat(2)1
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)2.41%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.72%
Revenue beat(12)3
Avg Revenue beat(12)-1.86%
Revenue beat(16)6
Avg Revenue beat(16)0.6%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.99%
EPS NQ rev (3m)1.18%
EPS NY rev (1m)-15.71%
EPS NY rev (3m)-12.08%
Revenue NQ rev (1m)-1.88%
Revenue NQ rev (3m)-5.36%
Revenue NY rev (1m)-2.61%
Revenue NY rev (3m)-4.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.78 | ||
| Fwd PE | 27.12 | ||
| P/S | 2.9 | ||
| P/FCF | 27.96 | ||
| P/OCF | 16.35 | ||
| P/B | 1.13 | ||
| P/tB | 1.27 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.88%
EPS(NY)9.8
Fwd EY3.69%
FCF(TTM)9.51
FCFY3.58%
OCF(TTM)16.26
OCFY6.12%
SpS91.66
BVpS234.62
TBVpS209.47
PEG (NY)N/A
PEG (5Y)3.29
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.69% | ||
| ROE | -28.07% | ||
| ROCE | 3.42% | ||
| ROIC | 2.7% | ||
| ROICexc | 3.32% | ||
| ROICexgc | 3.68% | ||
| OM | 11.85% | ||
| PM (TTM) | N/A | ||
| GM | 53.77% | ||
| FCFM | 10.37% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score6
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 4.51 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.36% | ||
| Interest Coverage | -6.54 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.48 | ||
| Quick Ratio | 4.85 | ||
| Altman-Z | 3.69 |
F-Score6
WACC10.98%
ROIC/WACC0.25
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.4%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%-6.45%
EPS Next Y-4.93%
EPS Next 2Y5.37%
EPS Next 3Y5.75%
EPS Next 5Y7%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-2.01%
Revenue Next Year0.27%
Revenue Next 2Y2.5%
Revenue Next 3Y3.15%
Revenue Next 5Y3.94%
EBIT growth 1Y-16.75%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year51.6%
EBIT Next 3Y21.87%
EBIT Next 5Y18.16%
FCF growth 1Y21.96%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y21.41%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%